A. Use of medical terminologies to describe adverse event terms in ClinicalTrials.gov (CROSBI ID 645848)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Pranić, S ; Mahmić-Kaknjo, M ; Marušić A
engleski
A. Use of medical terminologies to describe adverse event terms in ClinicalTrials.gov
Objective: To describe type and variability of medical terminology used for adverse event terms in ClinicalTrials.gov in context of mandates by the Food and Drug Administration Amendments Act of 1997 to promote transparency surrounding reporting of trial data. Study Design and Setting: Cross- sectional study on safety and efficacy trials in ClinicalTrials.gov for common drugs: antidepressants, analgesics or anesthetics, antidepressants, anti-allergics, anti-infectives, enzyme inhibitors, and anti-inflammatory, antineoplastic, hypoglycemic, neuromuscular agents. Methods: Registered and completed clinical trials with adverse events between 2009 and 2012. We chose trials of 10 drug categories from safety and efficacy trials. We excluded trials without drug intervention or adverse events. Results: Out of 93 trials that studied drugs, pain was most studied (n = 5, 5.4%), followed by major depressive disorder (n = 4, 4.3%). Most trials were randomized (n = 63, 67.7%). MedDRA was most commonly used (n = 30, 32.3% and n = 45, 48.44%) dictionary for serious and other adverse events (SAEs and OAEs), respectively. Predominantly, 67 (72%) trials reported OAEs, whereas 42 (45.2%) reported SAEs. Majority (n = 51, 54.8%) of drugs were an FDA indication. Omitted medical terminology sources were 10 (10.8%) for trials with SAEs and 18 (19.4%) for OAEs. Of 236 lay terms for both SAEs and OAEs, same lay term defined up to 3 different adverse events in 11 (11.8%) and 69 (74.2%) trials, respectively. Conclusion: MedDRA was predominantly used to define adverse events from trials. Many studies failed to provide a source dictionary. Without a ClinicalTrials.gov requirement for a standard dictionary, there may be a reduction in comparability of adverse events across studies. Administrators at ClinicalTrials.gov may consider the peremptory use of MedDRA or lay terms.
side effects ; Clinical Trial as Topic ; Data Bases as Topic ; Biomedical Ontologies
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
171-171.
2016.
objavljeno
Podaci o matičnoj publikaciji
Seoul:
0-000-00000-0
0000-000X
Podaci o skupu
The 24th Cochrane Colloquium
poster
23.10.2016-27.10.2016
Seoul, Republika Koreja